An interventional study of Experimental Group in Type 2 Diabetes and Type 2 Diabetes Patients, sponsored by Ataturk University. Completed at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Ataturk University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 61 open to participants now, 71 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.
Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 197th largest by enrollment of the 266 interventional ones that give a count, is one of 26 that started in 2025, is one of 150 with no phase, and was the 241st registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →61 of the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–65
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Hatice Zehra FERHATLAR · Sites in Turkey
Ages 18–65
Ankara Medipol University · Sites in Turkey
Ages 18–74
AstraZeneca · Sites in Turkey, United States, Argentina and 8 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 85 · Phase 4 28
First in 2002; this study’s year is marked. 26 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 266 interventional studies, 118 across the 75 observational. Of the 261 that completed or were terminated, 80 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 342 have an industry lead sponsor. The 10 most frequent:
Ataturk University is the lead sponsor of 463 studies on the registry; 123 are open to participants now.
Ataturk University has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
25 of the studies in Diabetes Mellitus, Type 2 with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847294Ankara Medipol UniversityThe Effectiveness of an Occupation-Based Lifestyle Program in Individuals With Type 2 Diabetes | 2026-11 |
| NCT07659925Baskent UniversityPeriodization-Based Strength Exercise Training in İndividuals With Type 2 Diabetes | 2026-11 |
| NCT07734428Istanbul Bilgi UniversityInflammation and Diabetes: Evaluating Antioxidant Levels | 2026-12-30 |
| NCT07649967Selcuk UniversityValidity and Reliability of Mixed Reality-Based Functional Mobility Tests in Type 2 Diabetes | 2026-12-30 |
| NCT06704672Hoffmann-La RocheClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus | 2027-01-15 |
Add all 25 to your calendar (.ics) → With an account.
Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to examine the effects on diabetes self-management, health fatalism and metabolic parameters of individuals with type 2 diabetes. The study will be conducted in a health institution between May 2025 and October 2025 and participants will be assigned to experimental and control groups by simple random sampling method. The experimental group will be trained with motivational interviewing techniques based on the health belief model for 8 weeks, followed by sending reminder SMS for 4 weeks. The control group will receive no intervention. The study is expected to improve the self-care behaviors of individuals with diabetes by creating positive effects on diabetes management and health fatalism.
Aim: The aim is to examine the effects of combining the Health Belief Model with Motivational Interviewing techniques on self-management behaviors, perceptions of health fatalism, and metabolic parameters in patients with type 2 diabetes.
Material and Method: This randomized controlled trial was conducted between July 2024 and April 2026. The sample consisted of a total of 62 individuals, including 31 experimental subjects and 31 controls. Data were collected using the "Identification Information Form," "Type 2 Diabetes Self-Management Scale", "Health Fatalism Scale" and "Metabolic Control Monitoring Form." In the experimental group, an 8-week training program based on the Health Belief Model and Motivational Interviewing was implemented; during the 4-week period following the training, support was provided via weekly SMS messages. No intervention was made in the control group. After 3 months, the scales were reapplied to both groups. The data were analyzed using SPSS 22, and t-tests, Mann Whitney U, Wilcoxon, and chi-square tests were used.
Conclusion: Motivational interviews based on the Health Belief Model have been found to increase self-management, reduce health fatalism, and improve metabolic parameters in individuals with type 2 diabetes. Accordingly, it is recommended that this approach be integrated into nursing practices in diabetes care, particularly in primary healthcare settings.
Key Words: Health belief model, health fatalism, metabolic parameters, motivational interviewing, nursing, self-management, type 2 diabetes
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale will be applied to the experimental group before the training. then, diabetes education will be given to the individuals in the experimental group one day a week with the motivational interviewing technique based on the health belief model. 8 weeks of training will be given in total and then 4 weeks of informative reminder sms will be sent about diabetes education. After the training is over, Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale will be applied.
Other: Experimental Group
The control group will be administered the Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale at the first encounter. After 3 months, the Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale will be applied again. No application will be made to the control group.
individuals will receive diabetes education with motivational interviewing technique based on health belief model
Type 2 DM Self-Management Scale (SMS)
The scale assesses self-management It has 3 sub-dimensions.These dimensions consist of 11 questions consisting of "Healthy Lifestyle Behaviors" dimension, consisting of 4 questions "Health Services Utilization" dimension and "Blood Sugar Management" dimension. Scoring: Always 5, Often 4, Sometimes 3, Rarely 2, Never 1. (-Healthy Lifestyle Subdimension= HLBD-1+ HLBD-2+ HLBD-3+ HLBD-4+ HLBD-5+ HLBD-6+ HLBD-7+ SYBD-8+ SYBD-9+ SYBD-10+ SYBD-11.) (-Blood Glucose Management Subscale= BSM-1+ BSM-2+ BSM-3+ BSM-4) (-Health Services Utilization Subdimension= SHK-1+ SHK-2+ SHK-3+ SHK-4) (-Diabetes Self-Management Scale score=SMDI Subdimension+CSM Subdimension +SCC Subdimension.) There are no reverse items in the scale. High scores indicate good self-management, low scores indicate and poor self-management. The minimum score that can be obtained from the Type 2 self-management scale is 19 and the maximum score is 95.
Time frame: three months
Health Fatalism Scale
The scale consists of one sub-dimension and 17 items. The scale is a Likert-type scale answered as ''strongly disagree'', ''disagree'', ''undecided'', ''agree'', ''strongly agree''. The minimum score obtained from the Health Fatalism Scale is 17 and the maximum score is 85. Cronbach α Coefficient of the scale is 0.91.An increase in the score on the scale indicates an increase in fatalism.
Time frame: three months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Aug 2025, 3 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 3 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Feb 2025 → May 2025, primary completion May 2025 → Aug 2025 and completion Jun 2025 → Aug 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.